In the latest market close, Moderna (MRNA) reached $54.36 ... Meanwhile, the Dow lost 0.9%, and the Nasdaq, a tech-heavy index, lost 2.76%. The biotechnology company's shares have seen a decrease ...

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.

In trading on Monday, shares of Moderna Inc (Symbol: MRNA) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $53.41 per share. By comparison ...

U.S. stocks were higher after the close on Monday, as gains in the Consumer Goods, Financials and Industrials sectors led ...

Below is a chart showing LLY's trailing twelve month trading history, with the $830 strike highlighted in orange: Moderna Inc (Symbol: MRNA) options are showing a volume of 68,653 contracts thus ...

The upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of $1.91 per share, indicating a decline of 37.4% compared to the year-ago period. Analysts forecast revenues of $1.25 ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...